News Summary
Neuros Medical, Inc. has raised $56 million in an oversubscribed Series D financing round to support the commercialization of its Altius® Direct Electrical Nerve Stimulation System. Designed to alleviate chronic post-amputation pain, this groundbreaking FDA-approved system offers a non-opioid treatment alternative for the 80% of amputees affected by pain conditions. The funding, led by EQT Life Sciences, will enable further development of the Altius System, aiming to transform pain management for amputees.
Aliso Viejo, California – Neuros Medical, Inc. has successfully secured $56 million in an oversubscribed Series D financing round, as announced on July 9, 2025. The funding is intended to support the U.S. commercialization and further development of the Altius® Direct Electrical Nerve Stimulation System, a groundbreaking FDA-approved non-opioid treatment specifically designed to alleviate chronic post-amputation pain.
This significant financial boost was spearheaded by EQT Life Sciences, a new investor, alongside participation from existing investors including US Venture Partners, Amzak Health, Osage University Partners, Sectoral Asset Management, and Aperture Venture Partners. This diverse range of backing illustrates substantial investor confidence in the potential impact of the Altius System on the lives of individuals affected by chronic post-amputation pain.
The Altius System uniquely addresses the underlying causes of post-amputation pain, which affects approximately 80% of amputees. This condition is often inadequately managed with existing treatment options, primarily opioids and gabapentinoids. Operated with a user-friendly interface, the Altius System is equipped with a nerve cuff electrode that wraps around the affected nerve and an implantable pulse generator (IPG). Patients can initiate a 30-minute treatment session on demand, delivering tailored pain relief targeted to their specific needs.
The pioneering device is aimed at managing chronic intractable phantom and residual lower limb pain in adult amputees. With nearly two million amputees currently residing in the U.S. and approximately 300,000 new amputations occurring each year, the need for innovative pain management solutions is more pressing than ever.
Neuros Medical, a privately held company based in Aliso Viejo, emphasizes a mission to improve the quality of life for amputees through patent prioritization, excellence in delivery, responsible ambition, and empowerment of patients and healthcare professionals. The company is driven by core values that underscore commitment to patient care, which is reflected in the comprehensive development of the Altius System.
EQT Life Sciences has highlighted its belief in the Altius System’s capability to significantly enhance quality of life for amputees navigating the challenges of chronic pain. The funding secured will allow Neuros Medical to advance its mission further and refine the technology behind the Altius System, setting the stage for medical advancements that could revolutionize treatment strategies for chronic post-amputation pain.
The successful closure of this financing round marks a pivotal moment for Neuros Medical as it aspires to forge deeper connections with healthcare providers and patients alike. This funding not only facilitates the commercialization phase but also serves as a crucial endorsement of the potential for non-opioid solutions in managing pain associated with amputation.
Deeper Dive: News & Info About This Topic
HERE Resources
Additional Resources
- FinSMEs: Neuros Medical Raises $56M in Series D Funding
- Wikipedia: Chronic Pain
- MassDevice: Neuros Medical Raises $56M Series D
- Google Search: Altius Direct Electrical Nerve Stimulation System
- News Journal: Neuros Medical Secures $56M Series D
- Google Scholar: Neuros Medical
- PR Newswire: Terumo Neuro Receives FDA Approval
- Encyclopedia Britannica: Amputation
- BioWorld: Neuros Reports Altius Reduces Pain
- Google News: Intractable Phantom Pain
